HK1175071A1 - Lenalidomide and thalidomide immunoassays - Google Patents
Lenalidomide and thalidomide immunoassaysInfo
- Publication number
- HK1175071A1 HK1175071A1 HK13102423.8A HK13102423A HK1175071A1 HK 1175071 A1 HK1175071 A1 HK 1175071A1 HK 13102423 A HK13102423 A HK 13102423A HK 1175071 A1 HK1175071 A1 HK 1175071A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- lenalidomide
- thalidomide
- immunoassays
- thalidomide immunoassays
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/722,829 US8114621B2 (en) | 2010-03-12 | 2010-03-12 | Lenalidomide and thalidomide immunoassays |
| PCT/US2011/025883 WO2011112358A1 (en) | 2010-03-12 | 2011-02-23 | Lenalidomide and thalidomide immunoassays |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1175071A1 true HK1175071A1 (en) | 2013-06-28 |
Family
ID=44560359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13102423.8A HK1175071A1 (en) | 2010-03-12 | 2013-02-26 | Lenalidomide and thalidomide immunoassays |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8114621B2 (xx) |
| EP (1) | EP2544540B1 (xx) |
| JP (1) | JP2013522594A (xx) |
| CN (2) | CN104730254A (xx) |
| AU (1) | AU2011224719B2 (xx) |
| BR (1) | BR112012023015A2 (xx) |
| CA (1) | CA2790508A1 (xx) |
| HK (1) | HK1175071A1 (xx) |
| WO (1) | WO2011112358A1 (xx) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029548B2 (en) * | 2011-05-06 | 2015-05-12 | Catabasis Pharmaceuticals, Inc. | Fatty acid lenalidomide derivatives and their uses |
| PT2888284T (pt) | 2012-08-21 | 2022-11-18 | Janssen Pharmaceutica Nv | Anticorpos dirigidos contra haptenos de risperidona e a sua utilização |
| PT2888590T (pt) | 2012-08-21 | 2020-09-11 | Janssen Pharmaceutica Nv | Anticorpos para olanzapina e utilização destes |
| CA2882595C (en) | 2012-08-21 | 2019-06-04 | Ortho-Clinical Diagnostics, Inc. | Antibodies to olanzapine haptens and use thereof |
| EP2888287A4 (en) | 2012-08-21 | 2016-04-20 | Ortho Clinical Diagnostics Inc | ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE |
| PT3462173T (pt) | 2012-08-21 | 2021-04-28 | Janssen Pharmaceutica Nv | Anticorpos contra risperidona e utilização dos mesmos |
| CN104736561B (zh) | 2012-08-21 | 2018-06-12 | 詹森药业有限公司 | 帕潘立酮的抗体及其用途 |
| WO2014121033A1 (en) | 2013-02-04 | 2014-08-07 | Fl Therapeutics Llc | Soluble complexes of drug analogs and albumin |
| WO2015200837A1 (en) | 2014-06-27 | 2015-12-30 | Fl Therapeutics Llc | Abiraterone derivatives and non-covalent complexes with albumin |
| US10201617B2 (en) * | 2014-10-24 | 2019-02-12 | Zhuhai Beihai Biotech Co., Ltd. | 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin |
| US10444250B2 (en) | 2015-12-17 | 2019-10-15 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
| IL295603B2 (en) | 2017-09-22 | 2024-03-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| MX2020006812A (es) | 2017-12-26 | 2020-11-06 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019241274A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
| US20220356185A1 (en) * | 2018-07-06 | 2022-11-10 | Kymera Therapeutics, Inc. | Mertk degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| EP3886904A4 (en) | 2018-11-30 | 2022-07-13 | Kymera Therapeutics, Inc. | IRAQ-TYPE KINASE DEGRADING AGENTS AND THEIR USES |
| EP4009979A4 (en) * | 2019-08-09 | 2023-08-23 | The Regents of the University of California | ANTIBODY-BASED CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES AND THEIR APPLICATIONS |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US11779578B2 (en) | 2019-12-17 | 2023-10-10 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021133920A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| JP2023518423A (ja) | 2020-03-19 | 2023-05-01 | カイメラ セラピューティクス， インコーポレイテッド | Ｍｄｍ２分解剤およびそれらの使用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| WO2022072538A1 (en) * | 2020-09-30 | 2022-04-07 | Biotheryx, Inc. | Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications |
| TW202304525A (zh) * | 2021-04-14 | 2023-02-01 | 南韓商樂高化學生物科學股份有限公司 | 蛋白質降解劑偶聯物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3996344A (en) | 1972-05-15 | 1976-12-07 | Biological Developments, Inc. | Phenethylamine antigenic conjugates, their preparation, antibodies and use |
| US4016146A (en) | 1974-12-10 | 1977-04-05 | Biological Developments, Inc. | Phenethylamine antigenic conjugates, their preparation, antibodies, and use |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20060024768A1 (en) * | 2004-07-29 | 2006-02-02 | Saladax Biomedical, Inc. | Taxol immunoassay |
| US20060216767A1 (en) * | 2005-03-22 | 2006-09-28 | Saladax Biomedical Inc. | Docetaxel immunoassay |
| US7569358B2 (en) * | 2005-03-30 | 2009-08-04 | Saladax Biomedical Inc. | Doxorubicin immunoassay |
| US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
| CN101501071A (zh) * | 2006-05-31 | 2009-08-05 | Lpath公司 | 对溶血磷脂酸具有反应性的免疫衍生部分 |
| US8268592B2 (en) * | 2008-07-17 | 2012-09-18 | Kyowa Hakko Kirin Co., Ltd | Anti-system ASC amino acid transporter 2 (ASCT2) antibody |
-
2010
- 2010-03-12 US US12/722,829 patent/US8114621B2/en not_active Expired - Fee Related
-
2011
- 2011-02-23 AU AU2011224719A patent/AU2011224719B2/en not_active Ceased
- 2011-02-23 CN CN201510145557.9A patent/CN104730254A/zh active Pending
- 2011-02-23 CN CN201180013575.1A patent/CN102917587B/zh not_active Expired - Fee Related
- 2011-02-23 JP JP2012557073A patent/JP2013522594A/ja active Pending
- 2011-02-23 CA CA2790508A patent/CA2790508A1/en not_active Abandoned
- 2011-02-23 EP EP11753786.0A patent/EP2544540B1/en not_active Not-in-force
- 2011-02-23 WO PCT/US2011/025883 patent/WO2011112358A1/en active Application Filing
- 2011-02-23 BR BR112012023015A patent/BR112012023015A2/pt not_active IP Right Cessation
- 2011-11-22 US US13/302,844 patent/US8293492B2/en active Active
- 2011-11-23 US US13/303,356 patent/US8440796B2/en active Active
-
2013
- 2013-02-26 HK HK13102423.8A patent/HK1175071A1/xx not_active IP Right Cessation
- 2013-03-28 US US13/852,523 patent/US20140024807A1/en not_active Abandoned
- 2013-03-28 US US13/852,308 patent/US20130211052A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012023015A2 (pt) | 2017-06-06 |
| CN102917587A (zh) | 2013-02-06 |
| AU2011224719B2 (en) | 2014-10-23 |
| US20140024807A1 (en) | 2014-01-23 |
| EP2544540A1 (en) | 2013-01-16 |
| US20120064549A1 (en) | 2012-03-15 |
| EP2544540A4 (en) | 2013-08-07 |
| US8440796B2 (en) | 2013-05-14 |
| AU2011224719A1 (en) | 2012-09-06 |
| WO2011112358A1 (en) | 2011-09-15 |
| US20130211052A1 (en) | 2013-08-15 |
| CA2790508A1 (en) | 2011-09-15 |
| US20110223611A1 (en) | 2011-09-15 |
| EP2544540B1 (en) | 2015-04-08 |
| US8114621B2 (en) | 2012-02-14 |
| CN102917587B (zh) | 2015-04-29 |
| US20120071632A1 (en) | 2012-03-22 |
| JP2013522594A (ja) | 2013-06-13 |
| US8293492B2 (en) | 2012-10-23 |
| CN104730254A (zh) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1175071A1 (en) | Lenalidomide and thalidomide immunoassays | |
| HK1184736A1 (zh) | 用於心包進入的方法和器件 | |
| GB2481366B (en) | Entertainment device and entertainment methods | |
| EP2533848A4 (en) | ACCESS DEVICE | |
| EP2523708A4 (en) | DEVICE | |
| ZA201203643B (en) | Access device | |
| GB201004106D0 (en) | Device | |
| GB201012154D0 (en) | Closure device | |
| EP2446807A4 (en) | ENDOSKOPHALTENDE DEVICE | |
| EP2586058A4 (en) | MEMORY DEVICE | |
| EP2634334A4 (en) | HINGE DEVICE AND BASE FOR HINGE DEVICE | |
| EP2544623A4 (en) | AUTOMATIC CLOSURE DEVICES AND METHODS FOR THEIR MANUFACTURE AND USE | |
| ZA201300693B (en) | Tube-feed packages and methods for using same | |
| EP2618133A4 (en) | OPTICAL-ELECTRIC FIELD REINFORCING DEVICE | |
| EP2722625A4 (en) | SHREDDING AND DRYING DEVICE | |
| EP2581613A4 (en) | JOINT DEVICE | |
| ZA201203644B (en) | Access device | |
| GB201005963D0 (en) | Device | |
| EP2541588A4 (en) | PLATINUM DEVICE | |
| EP2555192A4 (en) | AUDIO DEVICE | |
| GB201015349D0 (en) | Memory device | |
| IL220948A0 (en) | Podiatric device | |
| EP2557623A4 (en) | POWER GENERATION DEVICE | |
| PL2426282T3 (pl) | Urządzenie spłukujące | |
| GB2476327B (en) | Audio device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230221 |